Cystatin B is a progression marker of human epithelial ovarian tumors mediated by the TGF-β signaling pathway

Wang, Xingxing; Gui, Lu; Zhang, Youyuan; Zhang, Jihong; Shi, Jimin; Xu, Guoxiong

doi:10.3892/ijo.2014.2261

Cited by 37 publications

(45 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The immunoreactive staining of COL5A1 in the tissue of a section was evaluated by two independent pathologists. COL5A1-low and -high expression in the breast tissue was determined as previously described (20,21).…”

Section: Methodsmentioning

confidence: 99%

Overexpression of collagen type V α1 chain in human breast invasive ductal carcinoma is mediated by TGF-β1

Ren

Zhang

et al. 2018

Int J Oncol

Self Cite

View full text Add to dashboard Cite

Collagen type V α1 chain (COL5A1) is a minor fibrillar collagen in mammals that co-polymerizes with type I collagen to adjust the diameter of collagen molecules. However, the function of COL5A1 in invasive ductal carcinoma (IDC) of the human breast remains unknown. In the present study, our group examined the expression of COL5A1 in IDC compared with its adjacent normal tissue and fibroadenoma of the breast. COL5A1 was revealed to be overexpressed in IDC compared with benign tumor and adjacent normal control tissues, and was associated with the expression of estrogen receptor and progesterone receptor. No association between COL5A1 expression and tumor size, lymph node metastasis, clinical stage, age, or Her2 expression was identified. High expression of COL5A1 mRNA was associated with distant metastasis free survival in patients with breast cancer. Knockdown of COL5A1 led to a decrease of cell viability, as detected by the WST-1 assay, and an inhibition of migration and invasion, as detected by wound healing and Transwell assays, respectively, in the breast cancer cell line MCF-7. The expression of COL5A1 in MCF-7 cells was downregulated by transforming growth factor (TGF)‑β1, which was abolished in the presence of SB-431542, an inhibitor of TGF-β type I receptor. In conclusion, these data indicated that COL5A1 is overexpressed in IDC and regulated by TGF-β1, suggesting that an increase of COL5A1 reflects tumor progression and may serve as a novel biomarker and therapeutic target for the treatment of breast IDC.

show abstract

Section: Methodsmentioning

confidence: 99%

Overexpression of collagen type V α1 chain in human breast invasive ductal carcinoma is mediated by TGF-β1

Ren

Zhang

et al. 2018

Int J Oncol

Self Cite

View full text Add to dashboard Cite

show abstract

“…Immunohistochemical staining and analysis. To evaluate the expression of NAMPT, VEGF and HER2 proteins in breast tumors, immunohistochemical staining was performed as described previously (19). Briefly, after blocking, the sections were incubated with a rabbit monoclonal anti-NAMPT, mouse monoclonal anti-VEGF or anti-HER2 antibody (all 1:250 dilution; Abcam, Cambridge, MA, USA) at 4˚C overnight, followed by incubation with biotinylated secondary antibody (1:150 dilution; Maixin Bio, Fuzhou, China) at room temperature for 1 h. After washing, the signal was detected using a DAB kit (diaminobenzidine; Maixin Bio).…”

Section: Methodsmentioning

confidence: 99%

“…The sections were evaluated at original magnification, x200. The proportion of cells exhibiting protein expression was scored by the extent of immunoreactive staining and was assigned to one of the following categories as described previously (19). Briefly, the percentage of positive cells was scored as follows: no reactivity as 0, ≤25% positive cells as 1, 26-50% positive cells as 2, 51-75% positive cells as 3 and >75% positive cells as 4.…”

Section: Methodsmentioning

confidence: 99%

Biomarker triplet NAMPT/VEGF/HER2 as a de novo detection panel for the diagnosis and prognosis of human breast cancer

et al. 2015

Self Cite

View full text Add to dashboard Cite

The early detection of breast cancer, the most common malignant tumor disease in women worldwide, relies on mammography and self breast examination. Here we evaluated the concentration of nicotinamide phosphoribosyltransferase (NAMPT), vascular endothelial growth factor (VEGF) and human epidermal growth factor receptor-2 (HER2) in serum and their expression in breast tissues associated with the clinicopathological features of patients with benign and malignant breast tumors. The immunohistochemical analysis showed that NAMPT, VEGF and HER2 proteins were overexpressed in breast tumors. The highest expression was observed in malignant tumors, low in benign tumors and negative in the adjacent normal tissue, indicating that the triplets may be progression markers and correlated with each other. The detection rate of NAMPT, VEGF and HER2 alone in tissue was 54.17, 64.58 and 60.42%, respectively, and was increased to about 79% in double combination and to 90% in triple combination. The basal levels of serum NAMPT, VEGF and HER2 in healthy controls were 94.90±4.24 pg/ml, 87.02±2.41 pg/ml and 1.12±0.04 ng/ml, respectively, measured by ELISA and found to be increased by 6.64-, 1.76- and 2.52-fold, respectively, in patients with malignant breast tumor. These elevated serum levels of NAMPT, VEGF and HER2 in patients were decreased after tumor removal, suggesting that these molecules are the indicators of treatment efficacy. The combined measurement of these triplets together may improve the sensitivity of breast cancer diagnosis and may potentially be used as a testing panel for the detection of malignant tumors, the assessment of treatment effectiveness and the monitoring of the disease progression in patients with breast cancer. Thus, we propose that the biomarker triplet NAMPT/VEGF/HER2 can be used as a de novo detection panel for the diagnosis and prognosis of human breast cancer.

show abstract

“…The sections were evaluated at two magnifications (x100 and x400). The proportion of cells exhibiting Nampt expression was scored by the extent of immunoreactive staining and was assigned to one of the following categories as described previously 26 . Briefly, the percentage of positive cells was scored as given in the following: 0, no positive cells; 1, ≤25% positive cells; 2, 26-50% positive cells; 3, 51-75% positive cells; 4, >75% positive cells.…”

Section: Methodsmentioning

confidence: 99%

Regulative Effect of Nampt on Tumor Progression and Cell Viability in Human Colorectal Cancer

Lv¹,

Zhang²,

Zhu³

et al. 2015

J. Cancer

Self Cite

View full text Add to dashboard Cite

Colorectal cancer (CRC) is the third most common cancer disease. Here we examined Nampt expression in patients with CRC and the effect of Nampt on cell viability in CRC cells. Nampt protein was overexpressed in colorectal adenoma as well as colorectal carcinoma. The immunoreactive staining of Nampt was negative in the adjacent normal colorectal tissue, weak in colorectal adenoma, and strong in colorectal carcinoma, which may represent tumor progression. Further evaluation of clinical data showed that Nampt expression was not correlated with the clinicopathological characteristics of CRC. Additionally, our in vitro studies demonstrated that Nampt promotes CRC cell viability, whereas the Nampt inhibitor FK866 suppressed CRC cell viability, which was in concordance with the previous studies in other cancer cells. Treatment with Nampt-siRNA reduced the Nampt protein expression resulting in the inhibition of the cell viability of HCT116 and Caco2. Thus, the involvement of Nampt in cell growth indicates that Nampt may play an important role in colorectal tumorigenesis. As a consequence, our results suggest that Nampt may be considered as a progression marker of colorectal tumor and a potentially therapeutic target for the treatment of CRC.

show abstract

Cystatin B is a progression marker of human epithelial ovarian tumors mediated by the TGF-β signaling pathway

Cited by 37 publications

References 34 publications

Overexpression of collagen type V α1 chain in human breast invasive ductal carcinoma is mediated by TGF-β1

Overexpression of collagen type V α1 chain in human breast invasive ductal carcinoma is mediated by TGF-β1

Biomarker triplet NAMPT/VEGF/HER2 as a de novo detection panel for the diagnosis and prognosis of human breast cancer

Regulative Effect of Nampt on Tumor Progression and Cell Viability in Human Colorectal Cancer

Contact Info

Product

Resources

About